Testosterone Replacement Therapy: Options, Monitoring, Fertility and Safety

Evidence reviewed: 8 November 2026. Testosterone replacement therapy (TRT) is a prescribed treatment for selected men with confirmed hypogonadism—a clinical condition involving compatible symptoms and repeatedly low testosterone due to testicular or hypothalamic–pituitary dysfunction. TRT is not a universal anti-aging treatment, and it can suppress sperm production. Decisions require proper diagnosis, discussion of expected benefit, and continued monitoring of testosterone, hematocrit, blood pressure and relevant prostate risks. The 2026 European Association of Urology (EAU) guidance and recent US FDA updates clarify important safety considerations [1–4].

First confirm the diagnosis—not just a low number

Before prescribing TRT, clinicians should confirm symptoms or signs of androgen deficiency and at least two separate low early-morning testosterone measurements. The 2026 EAU guideline recommends sampling between 7 and 10 AM while fasting, using a reliable assay and repeating an abnormal result. SHBG and calculated free testosterone can improve interpretation when binding-protein levels are abnormal, for example in obesity or liver disease [1].

LH, FSH and sometimes prolactin help identify primary testicular disease versus secondary hypothalamic–pituitary causes. Clinicians should review medications, obesity, sleep apnea, diabetes, alcohol, depression and recent illness. Fatigue and erectile symptoms alone do not establish a hormone deficiency. A man whose testosterone is normal should not be started on TRT simply because an online symptom checklist scores highly [1,2].

For more detail on diagnosis, read our companion low-testosterone symptoms and blood-testing guide.

Who may benefit from TRT?

In men with properly established hypogonadism, restoring testosterone to a physiological range may improve sexual desire, some sexual symptoms, anemia, body composition or bone density, depending on the cause and individual situation. Benefits are not guaranteed, and some outcomes require additional treatment. A man with erectile dysfunction due to vascular disease may continue to need cardiovascular risk management or an erectile-dysfunction medicine even if testosterone deficiency is corrected [1,2].

The Endocrine Society’s July 2026 statement supports appropriate replacement for established disease and emphasizes weight loss as the usual first-line approach for functional testosterone reduction related to obesity when no other cause has been found. It advises against routine population screening and using TRT for nonspecific wellness concerns [2].

Choosing a testosterone formulation

Option Potential advantages Practical safety considerations
Transdermal gels or solutions Daily use may provide relatively stable levels and allow dose adjustment. Transfer to partners or children through skin contact; follow application, handwashing and clothing instructions.
Intramuscular or subcutaneous injections Flexible intervals and commonly available formulations. Peak–trough variation, local reactions and greater erythrocytosis risk with some regimens; laboratory timing matters.
Transdermal patches Can provide ongoing delivery without injections. Skin irritation; availability varies by country.
Oral testosterone undecanoate Oral delivery in countries where authorized. Product-specific meal instructions, blood-pressure warnings, interactions and monitoring.
Subcutaneous pellets Less frequent administration. Minor procedure, extrusion/infection risk and less immediate dose adjustment.

There is no one best formulation for every patient. Cost, access, adherence, dose adjustment, preference, skin tolerance, fertility intentions and comorbidity determine the choice. Formulation-specific testing is essential: serum testosterone sampling may be timed differently for gels, injections and other products [1]. Do not substitute compounded or unregulated “testosterone boosters” for approved prescription therapy.

Why TRT affects fertility

Exogenous testosterone suppresses pituitary LH and FSH through negative feedback. This reduces intratesticular testosterone and can substantially suppress spermatogenesis, causing low sperm counts or even no sperm in the ejaculate. The AUA/ASRM male infertility guideline states that clinicians should not prescribe exogenous testosterone to men seeking current or future fertility [3].

Recovery of sperm production after stopping may take months and, in some cases, much longer. Men who want children should discuss semen analysis and a reproductive-urology evaluation before starting TRT. Selected men with secondary hypogonadism may be candidates for gonadotropin-based or other specialist-directed fertility-preserving therapies; these are not suitable for self-medication.

Which safety tests should be performed before starting?

A baseline evaluation usually reviews blood pressure, hematocrit, prostate history and PSA when appropriate, sleep apnea, cardiovascular history, fertility plans and medication interactions. The 2026 EAU guideline recommends individualized prostate assessment and hematocrit monitoring; clinicians should consider whether prostate testing is appropriate based on age, risk and local screening guidance [1].

TRT may need to be deferred or avoided in a man with high hematocrit, untreated severe sleep apnea, uncontrolled severe heart failure, concerning prostate findings or an active malignancy requiring specialized management. No single checklist replaces comprehensive medical evaluation.

Monitoring after treatment begins

TRT requires ongoing follow-up rather than simply issuing repeated prescriptions. The 2026 EAU guideline recommends assessing testosterone and hematocrit at approximately 3, 6 and 12 months after initiation and then at least annually, with earlier or more frequent testing in higher-risk patients [1].

What to monitor Why it matters
Symptoms and treatment goals Determine whether sexual function or other relevant outcomes actually improve.
Serum testosterone Keep treatment in an appropriate physiological range and avoid excessive exposure.
Hematocrit Identify excessive red-cell production and potential thrombotic safety concerns.
Blood pressure Testosterone products can increase BP; adjust cardiovascular care when needed.
PSA and prostate evaluation Apply age-, risk- and indication-appropriate surveillance under local guidance.
Edema, sleep apnea, adverse effects Review tolerability and potential treatment complications.

Hematocrit above 54% during TRT is an important action threshold in the 2026 EAU guidance. Clinicians should hold or adjust therapy, evaluate contributing causes and consider specialist-directed venesection when indicated; treatment should not continue unchanged with very high hematocrit [1]. Patients should never perform blood donation or alter dosing as a substitute for professional evaluation.

What did the TRAVERSE trial show?

The large randomized TRAVERSE trial studied more than 5,200 men with confirmed hypogonadism and pre-existing or high cardiovascular risk. Its primary major adverse cardiovascular-event result did not show a meaningful difference between appropriately prescribed testosterone gel and placebo during the study period. The FDA revised boxed cardiovascular-warning language in February 2025 but separately required updated blood-pressure warnings [2,4].

The Endocrine Society’s July 2026 statement also highlighted an observed pulmonary embolism signal and more fractures in trial analyses and cautioned that evidence for very long-term safety remains incomplete [2]. “No significant difference in the primary cardiovascular endpoint” does not mean TRT has no risks, particularly outside trial eligibility and monitoring conditions.

How did FDA testosterone labeling change in 2026?

In June 2026, the FDA requested further revisions to testosterone product labeling after reanalysis of data, including changes concerning age-related hypogonadism wording and prostate-related safety information [5]. These regulatory changes do not establish that every older man with fatigue needs TRT; clinical-society guidance continues to emphasize appropriate diagnosis, reversible causes and shared decision-making [2].

Possible side effects

  • Erythrocytosis: hematocrit elevation, sometimes requiring treatment modification.
  • Acne, oily skin, breast tenderness, edema or worsening lower urinary symptoms in selected patients.
  • Blood-pressure changes and potential exacerbation of serious underlying cardiopulmonary disease.
  • Suppressed sperm production and impaired fertility.
  • Sleep apnea aggravation or changes in sleep symptoms in susceptible patients.
  • Transfer exposure from topical preparations and formulation-specific reactions.

Report chest pain, severe breathlessness, sudden neurological changes or painful swollen legs promptly as potential emergencies. Any new adverse effect warrants clinician review rather than unplanned dose escalation.

Testosterone and the prostate

Prostate assessment is an important component of shared decision-making, but it should not be oversimplified. TRT is not proven to cause every prostate cancer; neither is it unconditionally safe in the presence of suspected or untreated prostate malignancy. Men with elevated PSA or other concerning findings may require urological evaluation before initiating therapy. Individual risk is shaped by age, family history, inherited variants and other factors [1,5].

For screening decisions, see our companion prostate cancer PSA and screening guide. A change in PSA needs interpretation in context; it is not a direct readout of whether TRT has caused cancer.

When should therapy be reconsidered?

Reassess treatment when there is no meaningful improvement despite an appropriate trial, hematocrit rises excessively, blood pressure becomes difficult to control, adverse effects occur, fertility plans change or new contraindications emerge. Testosterone levels should not be driven above the normal physiological range to meet subjective gym-performance or anti-aging goals.

Some patients may benefit most from sleep treatment, weight management, optimizing medicines or addressing depression rather than TRT. These approaches can coexist with replacement when a genuine hypogonadal disorder has been established [1,2].

Frequently asked questions

Can I start testosterone after one low blood test?

No. The EAU and Endocrine Society recommend compatible symptoms and repeated appropriately timed testing [1,2].

Will TRT help me conceive a child?

It may impair fertility. Exogenous testosterone suppresses sperm production, and the AUA/ASRM guideline advises against it when current or future fertility is desired [3].

Is injectable testosterone better than gel?

Not universally. Monitoring, adherence, cost and adverse-effect differences guide formulation selection.

Is TRT completely safe for the heart after TRAVERSE?

No. The trial was reassuring for its primary cardiovascular outcome, but blood pressure, clotting signals and longer-term uncertainty remain [2,4].

Why is hematocrit checked?

Testosterone can increase red-blood-cell production. A hematocrit over 54% requires prompt clinical action [1].

Should every man over 50 use TRT?

No. Aging alone, without confirmed symptomatic deficiency and individualized evaluation, is not a sufficient indication [2].

Key takeaways

TRT is a monitored prescription treatment, not a wellness supplement. Confirm the diagnosis, discuss fertility before prescribing, choose an appropriate formulation, and monitor hematocrit, testosterone, blood pressure and prostate risk. Interpret recent FDA updates alongside the complete clinical evidence.

References

  1. European Association of Urology. 2026 guidelines on sexual and reproductive health: male hypogonadism. EAU; accessed 8 Nov 2026.
  2. Endocrine Society. Statement on testosterone replacement therapy. 16 July 2026.
  3. American Urological Association/American Society for Reproductive Medicine. Diagnosis and treatment of infertility in men: guideline, amended 2024.
  4. US Food and Drug Administration. FDA class-wide labeling changes for testosterone products. 28 February 2025.
  5. US Food and Drug Administration. Testosterone information and 2026 prescribing-label updates. Accessed 8 Nov 2026.

Medical disclaimer: Educational content only. TRT is prescription therapy requiring diagnosis and supervised monitoring. It can reduce fertility and cause serious adverse effects; do not start, stop or change treatment based on this article.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *